Survey on the use of REXULTI for managing aggressive behavior in Alzheimer's patients
Official title: REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Run by Otsuka Pharmaceutical Co., Ltd. · NCT06875986 · Data updated 2026-11-12
This study is testing if REXULTI can help manage aggressive behavior in people with Alzheimer's disease by looking at how well it works and its safety in everyday settings.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 15 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Osaka) |
| Status | Recruiting |
| Started | April 17, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | September 23, 2028 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06875986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with Alzheimer's disease who display excessive motor activity or aggressive behavior.
✕Probably not a fit
Patients who do not have a diagnosis of Alzheimer's disease or do not exhibit aggressive behaviors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the safety and efficacy of REXULTI (brexpiprazole) in patients diagnosed with Alzheimer's disease who exhibit excessive motor activity or aggressive behavior due to mood changes. The study will collect data from daily clinical settings to assess how well the medication performs in real-world scenarios. By monitoring patient responses and side effects, the study seeks to provide valuable insights into the drug's effectiveness for managing symptoms associated with Alzheimer's.
Why it matters
Potential benefit: If successful, this study could improve the management of aggressive behaviors in Alzheimer's patients, enhancing their quality of life.
How similar studies have gone: While this approach is observational, similar studies evaluating the efficacy of medications like REXULTI in managing behavioral symptoms in dementia have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with Alzheimer's disease Exclusion Criteria: \-
Where it's running
-
Pharmacovigilance Department
Osaka, Japan Recruiting
Study contacts
- Study coordinator: Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
- Email: komaniwa.satoshi@otsuka.jp
- Phone: +81-6-6943-7722
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.